SOURCES SOUGHT
66 -- Procurement of one Agilent xCELLigence Real-Time Cell Analyzer (RTCA) Dual Purpose (DP) System or Equivalent
- Notice Date
- 4/17/2020 8:52:52 AM
- Notice Type
- Sources Sought
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- NIH National Cancer Institute Rockville MD 20850 USA
- ZIP Code
- 20850
- Solicitation Number
- 75N91020Q00056
- Response Due
- 4/24/2020 8:00:00 AM
- Archive Date
- 05/09/2020
- Point of Contact
- Adam Hernandez, Phone: (240) 276-5633
- E-Mail Address
-
adam.hernandez@nih.gov
(adam.hernandez@nih.gov)
- Description
- This Small Business Sources Sought Notice (SBSS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Cancer Institute (NCI). The purpose of this Sources Sought Notice is to identify qualified small business concerns including 8(a), HUBZone or Service-Disabled Veteran-owned business concerns that are interested in and capable of performing the work described herein. The NCI does not intend to award a contract based on responses received nor otherwise pay for the preparation of any information submitted. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This requirement is assigned North American Industry Classification System (NAICS) code 334516 with a size standard of 1,000 employees is being considered. NCI may issue a request for quotation (RFQ) as a result of this Sources Sought Notice. THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NCI shall arise as a result of a response to this Sources Sought Notice or the NCI�s use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. 1.0�BRAND NAME OR EQUAL This requirement is for the procurement of the brand name or equivalent instrument described in section 3.0. The Federal Acquisition Regulation (FAR) provision FAR 52.211-6, Brand Name or Equal (AUG 1999) is applicable to this requirement. 2.0 BACKGROUND The U.S. Department of Health and Human Services (DHHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR), Urologic Oncology Branch (UOB) requires the procurement of an Agilent xCELLigence Real-Time Cell Analyzer (RTCA) Dual Purpose (DP) system or equivalent. The UOB studies hereditary urologic cancer at the clinical, genetic, and molecular levels. UOB performs clinical research contributing to the development of surgical and diagnostic procedures, and therapeutics against human Genitourinary Cancer. The required system will replace an old, unrepairable unit to support the ongoing establishment of the CCR Metabolomics Core and current projects. 3.0 PRODUCT FEATURES/SALIENT CHARACTERISTICS The following product features/characteristics are required for the greatest multiplexing capability which is necessary for analysis of limited patient samples or cell line types within UOB. The instrument shall: Include an electronic microtiter plate feature with micro-electrode configuration that covers 80% of each well bottom�s surface area. The real-time measurement of impedance across the electrodes provides sensitive immediate detection of the cellular condition and response from low cell numbers to confluency. This allows for examination of: Cell proliferation Cell quality Compound mediated cytotoxicity Cell-mediated cytotoxicity Cell adhesion and spreading Functional monitoring of receptor tyrosine kinase and G-protein-coupled receptors (GPCR) signaling Include a dual plate format to measure cellular chemotaxis with both migration and invasion spontaneously. Be optimized to study non-human as well as human cells. Include 24 to 48-hour cycle real-time monitoring reaction using impedance measurement repeatability: 0.5%. Be modular with precise quantitative and dynamic information. Have electrical input: +6V DC, 5 W max; Electronic switch resistance: 2-5 ohm. Have electrical interface: handling three electronic microtiter plates with 48 wells full capacity. Have the most specific parameter as monitoring tumor cell mobility profiling function available. Have the following build-in function for connection with computer instrumentation: RS232 serial communications at a band rate of 57600 bits/second. Have Impedance measure accuracy of: � (2% + 1.5 ohm; Real-time numeric and graphic data display. Real-time numeric and graphic data display. The software must be provided integrated data analysis, and able to be exported into MS� Excel for transfer into other statistical analysis programs, software must be unlimited-use license for NCI users. Include all the necessary consumables to perform real-time quantitative test for user selected output including design flexibility with wells on plates. Include a control unit (laptop) with preinstalled software for data display, acquisition, and analysis. 3.1 DELIVERY / INSTALLATION Delivery shall be within 90 business days of purchase order award. Upon delivery, the Contractor shall notify the NCI Technical Point of Contact (TPOC) to schedule the installation date and time that shall occur within 5 business days after delivery. Installation shall be performed by, or under the direct supervision of, a certified operator. The Contractor shall deliver and install the equipment at the following address: 10 Center Drive� Building 10 Room 1W-5888 Bethesda, MD 20892 3.2 TRAINING Within 30 business days after installation, at least one day of onsite training shall be provided for at least 25 users of the instrument.� 3.3 WARRANTY A minimum of 12-months warranty from the date of installation shall be included, which covers the cost of repair and/or replacement, including labor or any defect in workmanship or parts. 4.0 RESPONSE DELIVERY POINT Capability statements shall be submitted via email to Contract Specialist, Adam Hernandez, at adam.hernandez@nih.gov no later than 11:00 A.M. EST on Friday, April 24, 2020 (04/24/2020). All information furnished must be in writing and must contain enough detail to allow the NCI to determine if it can meet the unique specifications described herein. Please reference number 75N91020Q00056 on all correspondence. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization�s capability. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, an RFQ may be published. However, responses to this notice will not be considered adequate responses to a solicitation(s).
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/06fc83f255a94d1c8f9b96e15649c44b/view)
- Record
- SN05625318-F 20200419/200417230148 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |